Aceten 25mg Tab

Uses of Aceten 25mg Tab

Captopril is used in the treatment of hypertension and congestive heart failure. Captopril is an angiotensin-converting enzyme (ACE) inhibitor .

Side Effects of Aceten 25mg Tab

Nonproductive cough, dyspnoea, headache, abdominal pain, dry mouth, dizziness, GI and taste disturbances, sleep disorders. Hypotension, tachycardia, chest pain, palpitations, hyperkalaemia, hyponatremia, gynaecomastia (reversible). Pruritus, skin rashes, alopecia. Potentially Fatal: Anaphylactic reactions, angioedema. Fulminant hepatic necrosis.

Drug Interactions

Concurrent treatment w/ NSAIDs reduces hypotensive action and increases the risk of nephrotoxicity. Additive hyperkalaemic effect w/ K supplements, K-sparing diuretics, and other drugs (e.g. heparin). May increase risk of leucopenia w/ procainamide, allopurinol, cytostatic or immunosuppressants. May increase risk of lithium toxicity. Increased risk of nitritoid reactions w/ gold (Na aurothiomalate). Potentially Fatal: Increased risk of hypotension, hyperkalaemia, and changes in renal function (including acute renal failure) w/ aliskiren in diabetic patients.

Contraindications

Angioedema related to previous ACE inhibitor treatment, hereditary or idiopathic angioneurotic oedema. Concomitant use w/ aliskiren in diabetic patients. Pregnancy.

Mechanism of Action

Captopril competitively inhibits the conversion of angiotensin I (ATI) to angiotensin II (ATII), thus resulting in reduced ATII levels and aldosterone secretion. It also increases plasma renin activity and bradykinin levels. Reduction of ATII leads to decreased Na and water retention. This promotes vasodilation and BP reduction. Onset: 1-1.5 hr. Absorption: Rapidly absorbed from the GI tract (approx 60-75%). Reduced absorption w/ food. Time to peak plasma concentration: Approx 1 hr. Distribution: It crosses the placenta and enters breast milk (approx 1%). Plasma protein binding: Approx 30% (mainly albumin). Excretion: Via urine (40-50% as unchanged drug, the rest as disulfide and other metabolites). Elimination half-life: 2-3 hr.

Special Precautions

Patients w/ bilateral renal artery stenosis, collagen vascular disease, aortic or mitral valve stenosis, volume and/or Na depletion. Renal impairment. Lactation. Patient Counselling May impair ability to drive and operate machinery. Monitoring Parameters Monitor WBC count and urinary protein before and during therapy. Monitor renal function periodically.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.